Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C

Kawagishi, Naoki; Suda, Goki; Kimura, Megumi; Maehara, Osamu; Yamada, Ren; Tokuchi, Yoshimasa; Kubo, Akinori; Kitagataya, Takashi; Shigesawa, Taku; Suzuki, Kazuharu; Ohara, Masatsugu; Nakai, Masato; Sho, Takuya; Natsuizaka, Mitsuteru; Morikawa, Kenichi; Ogawa, Koji; Kudo, Yusuke; Nishida, Mutsumi; Sakamoto, Naoya

Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C

Kawagishi, Naoki; Suda, Goki; Kimura, Megumi et al.

Scientific reports, 2021, 11(1), 9207

Permalink : https://hdl.handle.net/2115/82232

このアイテムのアクセス数:686件（2026-08-18 21:40 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1038/s41598-021-88632-7			7

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/82232
タイトル	Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C
著者	Kawagishi, Naoki ; Suda, Goki ; Kimura, Megumi ; Maehara, Osamu ; Yamada, Ren ; Tokuchi, Yoshimasa ; Kubo, Akinori ; Kitagataya, Takashi ; Shigesawa, Taku ; Suzuki, Kazuharu ; Ohara, Masatsugu ; Nakai, Masato ; Sho, Takuya ; Natsuizaka, Mitsuteru ; Morikawa, Kenichi ; Ogawa, Koji ; Kudo, Yusuke ; Nishida, Mutsumi ; Sakamoto, Naoya
著者名 Kawagishi, Naoki
e-Rad_Researcher 20447460 著者名 Suda, Goki
著者名 Kimura, Megumi
著者名 Maehara, Osamu
著者名 Yamada, Ren
著者名 Tokuchi, Yoshimasa
著者名 Kubo, Akinori
著者名 Kitagataya, Takashi
著者名 Shigesawa, Taku
著者名 Suzuki, Kazuharu
著者名 Ohara, Masatsugu
著者名 Nakai, Masato
著者名 Sho, Takuya
著者名 Natsuizaka, Mitsuteru
著者名 Morikawa, Kenichi
著者名 Ogawa, Koji
著者名 Kudo, Yusuke
著者名 Nishida, Mutsumi
著者名 Sakamoto, Naoya
言語	英語
発行日	2021-04-28
出版者	Nature Research
収録物名	Scientific reports
巻(号)	11(1)
ページ	9207
抄録	We previously revealed that Angiopoietin-2 (Ang2) predicts non-regression of liver fibrosis based on liver stiffness measurement (LSM) at 24 weeks after anti-hepatitis C virus (HCV) treatment. In this study, we extended the observational period to 96 weeks to investigate the factors associated with non-regression after treatment with direct-acting-antivirals (DAAs). Patients treated with DAAs who underwent transient elastography at baseline and 24 and 96 weeks after DAA therapy were included. Baseline and post-treatment serum Ang2 levels were measured. Liver fibrosis stages were defined based on LSM. Multivariate regression was used to evaluate factors associated with non-regression of liver fibrosis between various time points. In total, 110 patients were included. Of these, 11% showed non-regression of LSM-based fibrosis stage at 96 weeks after DAA therapy. In multivariate analysis, advanced liver fibrosis stage and high baseline Ang2 levels were significantly associated with non-regression at 96 weeks. In patients with advanced liver fibrosis (F3/4), baseline Ang2 levels were associated with non-regression of liver fibrosis stage. Between SVR24 and SVR96, post-treatment Ang2 levels and controlled attenuation parameter values at SVR24 were significantly associated with non-regression of liver fibrosis stage in patients with F3/4. Thus, serum Ang2 levels are an important target for monitoring and therapy.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
PISSN	2045-2322
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1038/s41598-021-88632-7